Tech Company Financing Transactions
Atavistik Bio Funding Round
Nextech Invest, The Column Group and Lux Capital joined a $120 million Series B funding round for Atavistik Bio. The round was announced on 12/18/2025.
Transaction Overview
Company Name
Announced On
12/18/2025
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Series B
Investors
Nextech Invest (Lead Investor)
The Column Group (Lead Investor)
Proceeds Purpose
Atavistik Bio will use the proceeds from the Series B financing to advance its oral allosteric AKT1-selective inhibitor for HHT and its JAK2 V617F mutant-selective inhibitor program for MPNs through clinical proof of concept.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Atavistik Bio's high-throughput platform for the unbiased identification of metabolite-protein interactions, will enable us to discover first-in-class drugs inspired and empowered by nature's own mechanisms of allosteric control.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Josey
Founder
Ralph DeBerardinis
Founder
Jared Rutter
President
Marion Dorsch
Browse more venture capital transactions:
Prev: 12/18/2025: Cowboy venture capital transaction
Next: 12/18/2025: Orum Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs